HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NPCE
NeuroPace, Inc.
NPCE lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NPCE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NPCE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NPCE PE Valuation
NPCE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NPCE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
NPCE has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NPCE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.18 |
| Q2 2026 | -$0.57 | +$0.25 |
| Q1 2026 | -$0.65 | +$0.17 |
| Q4 2025 | -$0.66 | +$0.27 |
| Q3 2025 | -$0.74 | +$0.25 |
| Q2 2025 | -$0.82 | +$0.26 |
| Q1 2025 | -$0.82 | +$0.36 |
| Q4 2024 | -$0.93 | +$0.34 |
NPCE has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NPCE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NPCE on profitability, with a higher operating margin.
NPCE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.1M | -16% |
| Q2 2026 | $22.8M | -3% |
| Q1 2026 | $22.1M | -2% |
| Q4 2025 | $26.6M | +24% |
| Q3 2025 | $27.4M | +30% |
| Q2 2025 | $23.5M | +22% |
| Q1 2025 | $22.5M | +24% |
| Q4 2024 | $21.5M | +19% |
NPCE's revenue fell from its 2025 peak and has held roughly level since: $23M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9% | +0.5 points |
| Q2 2026 | -23% | +6.5 points |
| Q1 2026 | -25% | -2.4 points |
| Q4 2025 | -6.7% | +10 points |
| Q3 2025 | -9.5% | +11 points |
| Q2 2025 | -29% | +3.3 points |
| Q1 2025 | -23% | +19 points |
| Q4 2024 | -17% | +11 points |
NPCE's operating margin was −9% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NPCE on cash generation, producing positive trailing cash flow while its opponent burns cash.
NPCE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -$805K |
| Q2 2026 | -$4M | -$1.8M |
| Q1 2026 | -$6M | +$1.5M |
| Q4 2025 | $409K | +$5.2M |
| Q3 2025 | -$2M | -$150K |
| Q2 2025 | -$2.3M | +$1.7M |
| Q1 2025 | -$7.5M | +$113K |
| Q4 2024 | -$4.8M | -$1.5M |
NPCE has burned cash in almost every quarter: −$12M over the past year, against −$17M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NPCE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NPCE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +242K shares |
| 1 year | +3.7% | +1.2M shares |
| 3 years | +32% | +8.3M shares |
| 5 years | +96% | +16.8M shares |
NPCE has 34M diluted shares, up 3.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $49.5M |
| Q4 2020 | — |
NPCE hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NPCE Net Leverage
NPCE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NPCE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 7.3 | Oversold |
NPCE's weekly RSI is 39 (neutral) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NPCE PE vs Healthcare Sector
NPCE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NPCE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 5.2% below |
| 20 week MA | $14.0 | 14% below |
| 50 week MA | $15.0 | 20% below |
| 100 week MA | $13.3 | 9.4% below |
| 200 week MA | $10.6 | 14% above |
NPCE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NPCE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.4 | $9.73 | -62% |
| 2022 | $9.73 | $1.36 | -86% |
| 2023 | $1.36 | $10.3 | +658% |
| 2024 | $10.3 | $10.7 | +3.5% |
| 2025 | $10.7 | $16.0 | +50% |
| 2026 YTD | $16.0 | $12.0 | -25% |
NPCE has the edge over HIMS on returns for 2026, with the stronger performance.